Abstract 1194P
Background
Neuroendocrine tumors of the appendix are typically detected incidentally during appendectomy. A recent study reported no cases of metachronous metastases among patients with primary tumors <2cm, regardless of lymph node status or referral for completion hemicolectomy. However, questions persist regarding the possibility of metastases developing decades after surgery, particularly since appendiceal NETs are frequently diagnosed in young adults and children.We therefore sought to evaluate patients with metastatic appendiceal NETs to assess whether any had been diagnosed previously with an early stage appendiceal NET.
Methods
We analyzed a large institutional neuroendocrine tumor database to identify appendiceal NETs of all stages and ascertain whether any patients with localized tumors developed metastases, and whether any with metastatic disease had originally presented with an early-stage tumor.
Results
Out of over 5,000 patients seen in the neuroendocrine tumor clinic between 2008 and 2022, 95 were diagnosed with an appendiceal NET. Of these, only 6 patients (approximately 0.1% of total NET population) had stage 4 metastases, all diagnosed synchronously at time of initial diagnosis. All 6 patients had peritoneal disease. No patient with earlier-stage disease developed distant metastases.
Conclusions
Metastatic appendiceal NETs are exceptionally rare with a tendency to metastasize within the peritoneum. In all cases of stage 4 disease, metastases were observed at time of diagnosis. Our data provide further validation for the proposition that small local appendiceal NETs resected during appendectomy require no further surgery or surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
J. Strosberg: Financial Interests, Personal, Speaker’s Bureau: Ipsen, Tersera; Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13
1160P - Methods of nivolumab administration in advanced melanoma: A comparison of patients’ clinical outcomes treated with flat dose or weight-adjusted dose, FLATIMEL study
Presenter: Iona Campo le Brun
Session: Poster session 13
1161P - Therapeutic outcome of molecular profiling of melanoma patients resistant to standard treatment: Real-world data
Presenter: Madona SAKKAL
Session: Poster session 13
1162P - Prolonged exposure to proton pump inhibitors (PPI) at the time of initiation of immune checkpoint blockade (ICB) mediates better clinical outcomes in patients with metastatic melanoma
Presenter: Kyrillus Shohdy
Session: Poster session 13
1163P - CD39 affect the prognostic role of NLR via N2 neutrophils in metastatic melanoma patients treated with immunotherapy
Presenter: Domenico Mallardo
Session: Poster session 13
1164P - Changes of TCR repertoire in metastatic melanoma and renal cell carcinoma patients treated with nivolumab correlate with overall survival
Presenter: Martin Klabusay
Session: Poster session 13
1165P - Single cell spatial features of in-transit melanoma associated with patient outcome to immunotherapy
Presenter: Xinyu Bai
Session: Poster session 13
1166P - Multi-modal and longitudinal characterization of the tumor and immune microenvironment from primary melanoma to in-transit and distant metastasis
Presenter: Giuseppe Tarantino
Session: Poster session 13
1168P - Tumor PD-L1 predicts the outcome of PD-1-based immunotherapy in metastatic melanoma depending on the type of tissue examined
Presenter: Jan-Malte Placke
Session: Poster session 13
1169P - Tumour transcriptional and spatial protein profiling in Mexican patients reveals that acral lentiginous melanoma is characterized by an immunosuppressive microenvironment
Presenter: Martha Estefania Vázquez-Cruz
Session: Poster session 13